Antares Pharma Inc. (AIS) Gets New Drug Application Approval from FDA

QualityStocks would like to highlight Antares Pharma (NYSE AMEX: AIS). The company focuses on self-injection pharmaceutical products and topical gel-based medicines. The company's subcutaneous and intramuscular injection technology platforms include VibexTM disposable pressure-assisted auto injectors, ValeoTM/VisionTM reusable needle-free injectors, and disposable multi-use pen injectors.

In the company’s news Friday,

Antares Pharma announced that the New Drug Application (NDA) for Anturol® Gel as treatment for patients with overactive bladder (OAB) was accepted for filing for review by the U.S. Food and Drug Administration (FDA).

Anturol, a gel applied to the skin to treat OAB, incorporates Antares’ ATD Gel technology. Acceptance by the FDA marks an important milestone for the company as it works toward an approval that will give it commercial distribution of Anturol.

Antares said it the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of December 8, 2011, 10 months from the official NDA filing, at which time the FDA is expected to complete its review of the NDA, at which time the FDA is expected to complete its review of the NDA.

“The FDA’s acceptance for filing of the NDA for Anturol, Antares Pharma’s first NDA, is another notable achievement for the Company resulting from the dedicated efforts of the entire Antares team. This is an important accomplishment in the continued execution of our product focused strategy,” Paul K. Wotton Ph.D., president and CEO of Antares stated in the press release.

The Anturol NDA submission is supported by data from a 12-week, phase 3 randomized, double-blind, placebo-controlled clinical trial involving 600 patients with OAB. Results demonstrate that patients treated with Anturol daily experienced a significant decrease in OAB symptoms compared to administration of a placebo, including the number of urinary incontinence episodes per day. There were no reported serious treatment-related adverse events.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.